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Abstract
Introduction: Tumor infiltrating lymphocytes may indicate an immune response to cancer development, but their
significance remains controversial in breast cancer. We conducted this study to assess CD8+ (cytotoxic T)
lymphocyte infiltration in a large cohort of invasive early stage breast cancers, and to evaluate its prognostic effect
in different breast cancer intrinsic subtypes.
Methods: Immunohistochemistry for CD8 staining was performed on tissue microarrays from 3992 breast cancer
patients. CD8+ tumor infiltrating lymphocytes were counted as intratumoral when in direct contact with tumor
cells, and as stromal in adjacent locations. Kaplan-Meier functions and Cox proportional hazards regression models
were applied to examine the associations between tumor infiltrating lymphocytes and breast cancer specific
survival.
Results: Among 3403 cases for which immunohistochemical results were obtained, CD8+ tumor infiltrating
lymphocytes were identified in an intratumoral pattern in 32% and stromal pattern in 61% of the cases. In the
whole cohort, the presence of intratumoral tumor-infiltrating lymphocytes was significantly correlated with young
age, high grade, estrogen receptor negativity, human epidermal growth factor receptor-2 positivity and core basal
intrinsic subtype, and was associated with superior breast cancer specific survival. Multivariate analysis indicated
that the favorable prognostic effect of CD8+ tumor infiltrating lymphocytes was significant only in the core basal
intrinsic subgroup (Hazard ratio, HR = 0.35, 95% CI = 0.23-0.54). No association with improved survival was present
in those triple negative breast cancers that lack expression of basal markers (HR = 0.99, 95% CI = 0.48-2.04) nor in
the other intrinsic subtypes.
Conclusions: CD8+ tumor infiltrating lymphocytes are an independent prognostic factor associated with better
patient survival in basal-like breast cancer, but not in non-basal triple negative breast cancers nor in other intrinsic
molecular subtypes.
Introduction
Immune response may play an important role in cancer
progression. Tumor-infiltrating lymphocytes (TILs)
reflect a local immune response and could be a key
mechanism in controlling tumor progression [1,2]. A
number of studies demonstrate that TILs are associated
with clinical outcome in patients with carcinoma and
melanoma [3-8]. TILs have been found to be mainly T
lymphocytes, and the majority express a cytotoxic effec-
tor phenotype (CD8+) [9-11]. CD8+ T cell-mediated
type 1 immune responses can enhance the accumulation
of distinct endogenous CD8+ and CD4+ T cells and
facilitate their antitumor function within the tumor
microenvironment [12,13]. Studies in ovarian carcino-
mas and colon cancer show that high levels of CD8+
lymphocyte infiltration are associated with better prog-
nosis in these diseases [3,14]. In breast cancer, some
studies have reported that inflammation and cytotoxic
lymphocyte infiltration are associated with better survi-
val [15-17]. In contrast, other groups have reported that
high numbers of TILs are related to worse overall
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survival [18,19], whereas still other studies did not find
any significant association of TILs with patient outcome
[20,21]. A recent publication reported that a high ratio
of CD8+ TILs to FOXP3+ regulatory T cells had a signif-
icant relationship to improved patient survival in breast
cancer [22]. Two other studies have tested larger series:
one study used a retrospective cohort of 1,334 patients
with primary breast cancer diagnosed from 1987 to
1998 in the UK and showed that total CD8+ TILs were
independently associated with better survival in breast
cancer [23], whereas another study with 1,953 breast
cancer cases treated in the University Hospital Basel in
Switzerland between 1985 and 1996 demonstrated that
the independent favorable prognostic effect of total CD8
+ TILs was observed only in those with estrogen recep-
tor-negative (ER-) tumors (whereas, in univariate ana-
lyses, CD8+ TILs had an unfavorable effect on outcome
in ER-positive (ER+) breast cancers) [24]. Thus, the
extent to which TILs contribute to tumor progression
and clinical outcome in breast cancer has remained con-
troversial, possibly because the effect is limited to cer-
tain subgroups of patients.
Breast cancer is a heterogeneous disease composed of
different intrinsic subtypes, each with distinctive biologi-
cal and prognostic behaviors and responses to therapy.
Although the introduction of adjuvant systemic therapy
(AST) has led to a significant reduction in breast cancer
mortality, many patients do not benefit. Gene expression
studies suggest that predictive indicators should be
developed for different breast cancer subtypes [25,26].
The interaction between immune response, intrinsic
subtype, and treatment strategy all likely contribute to
the outcome of the disease. The development of mole-
cular diagnostic techniques has facilitated a better
understanding of the heterogeneity of breast cancer and
opened up the possibility of more personalized therapy
[27,28]. Hormone receptor status and human epidermal
growth factor receptor-2 (HER2) molecular status are
currently used to guide AST strategies for the luminal
and HER2+ intrinsic subgroups, but no targeted therapy
for the basal-like subgroup is currently available. Basal-
like breast cancer comprises about 15% of all invasive
breast cancers and is likely to be high-grade, occur in
young women, and have an aggressive clinical course
[29]. Although a majority of basal-like tumors carry a
clinical triple-negative phenotype (TNP) (ER-, progester-
one receptor-negative (PR-), and HER2-), they are not
synonymous [30], and triple-negative breast cancers
include many cases that lack the expression of basal
markers - the so-called ‘five-marker negative phenotype’
(5NP): ER-, PR-, HER2-, epidermal growth factor recep-
tor-negative (EGFR-), and cytokeratin (CK) 5/6- - which
have been shown to have significantly better outcomes
than core basal cases [31,32]. Gene expression profiling
data suggest that medullary breast tumors (a rare histo-
logical subtype with a prominent lymphocytic reaction
and a good prognosis) are a specific subgroup within
the basal-like class, indicating that the overall poor sur-
vival of basal-like breast cancer might be mitigated in
cases in which there is a strong immune response
[33-35]. On the other hand, a separate body of research
has highlighted that recruitment of chronic inflamma-
tory cells, including macrophages, can actually promote
cancer progression [36]. Different types of immune
response in different subtypes of breast cancer might
explain apparently contradictory results. However, to
date, no large immunohistochemistry study has explored
the prognostic effect of an immune response in breast
cancer stratified by breast cancer intrinsic subtype.
Therefore, there is a clear need for studies with suffi-
cient power for subgroup analysis, employing validated
measurements of immune response, to evaluate the sig-
nificance of TILs in breast tumors. The aim of this
study was to examine the prognostic significance of
CD8+ TILs in different breast cancer intrinsic subtypes
in a large population-based cohort with long-term fol-
low-up. Our hypothesis was that CD8+ lymphocyte infil-
tration has distinct prognostic effects in different
intrinsic molecular subtypes of breast cancer.
Materials and methods
Study population
The study population consists of 3,992 female patients
with invasive breast cancer diagnosed between 1986 and
1992 in the province of British Columbia. This cohort
was collected from the Breast Cancer Outcomes Unit
database maintained by the British Columbia Cancer
Agency (BCCA). During the study period, 75% of
patients with breast cancer in the province were referred
to the BCCA; non-referred patients were generally older
or had no indications for adjuvant therapy [37,38]. Of
the patients referred to the BCCA, approximately 25%
had available formalin-fixed paraffin-embedded blocks
with sufficient tumor tissues for tissue microarray
(TMA) construction. Thus, the study cohort represents
about 20% of all of the patients with breast cancer diag-
nosed in the province during the study period. The
mean age of the cohort at diagnosis was 58.9 years (23
to 95 years), and the median follow-up was 12.6 years.
Baseline clinical information of the study population
includes age at diagnosis, histology, grade, tumor size,
number of involved axillary nodes, lymphovascular inva-
sion (LVI), and dates of diagnosis, recurrence, death,
and cause of death (breast cancer versus other). As
shown in Table 1 among the study cases, approximately
half (51.1%, 2,040/3,992) were poorly differentiated
tumors (grade 3), 47.3% (1,888/3,992) had breast tumors
over 2 cm, 43.1% (1,719/3,992) were node-positive, and
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42.8% (1,710/3,992) had LVI. Histological categorization
on these cases, including assignment to the medullary
subtype, was determined by a central review of full sec-
tions which was performed at the time of referral to the
BCCA. During the time period of this study cohort,
most patients with breast cancer were treated according
to the provincial guidelines developed by the BCCA on
the basis of patient age, tumor size, nodal status, and
LVI. Patients were defined as high-risk if their lymph
nodes were positive, if there was evidence of LVI, or if
the tumor was both greater than 2 cm and ER- at the
time of diagnosis. High-risk patients were treated with
AST according to their age and menopausal status.
Low-risk patients were not given any AST. This study
and the use of de-identified data were approved by the
Clinical Research Ethics Board of the BCCA and the
University of British Columbia. We were permitted
access to the de-identified patient outcome information
from the Breast Cancer Outcomes Unit database, main-
tained by the BCCA. In compliance with the Canadian
Tri-Council Policy Statement for ethical research invol-
ving human subjects, the requirement for informed con-
sent was waived as this study was limited to anonymous
archival specimens.
Table 1 Clinicopathologic characteristics and distribution














< 40 294 (7.4) 38.9 (98/252)
40-49 844 (21.1) 37.5 (273/728)
50-65 1,425 (35.7) 31.3 (377/1,203)
> 65 1,429 (35.8) 29.2 (356/1,220)
Grade < 0.001
1: well differentiated 209 (5.2) 24.4 (40/164)
2: moderately well or
partially differentiated
1,563 (39.2) 26.9 (361/1,342)
3: poorly
differentiated





≤ 2 2,078 (52.1) 30.5 (540/1,768)
> 2-5 1,667 (41.8) 34.1 (494/1,449)
> 5 221 (5.5) 34.9 (59/169)
Unknown 26 (0.6)
Nodal status 0.051
Negative 2,265 (56.7) 31.0 (593/1,911)





Negative 2,106 (52.8) 32.5 (576/1,770)
Positive 1,710 (42.8) 31.8 (474/1,492)
Unknown 176 (4.4)
Histology < 0.001
Medullary 66 (1.7) 78.4 (40/51)
Not medullary 3926 (98.3) 31.7 (1,064/3,352)
AJCC stage 0.004
I 1,393 (34.9) 28.8 (337/1,172)
II 2,255 (56.5) 34.6 (677/1,959)







1,676 (42.0) 21.2 (302/1,427)
Tamoxifen only 1,276 (32.0) 18.6 (206/1,105)
Chemotherapy only 727 (18.2) 27.2 (169/622)
Tamoxifen +
chemotherapy
297 (7.4) 29.4 (73/148)
Other 16 (0.4) 21.4 (3/14)
ER < 0.001
Negative 1,200 (30.1) 39.9 (370/927)
Table 1 Clinicopathologic characteristics and distribution
of CD8+ intratumoral lymphocytes in the study popula-
tion (Continued)
Positive (≥ 1% nuclei
stained)





Negative 3,316 (83.1) 31.3 (907/2,902)





Luminal A 1,518 (38.0) 25.4 (353/1,392)
Luminal B 829 (20.8) 36.9 (285/773)
Luminal/HER2 224 (5.6) 39.8 (82/206)
Luminal not further
assigned
244 (6.1) 21.5 (37/172)
HER2+/ER- 250 (6.3) 39.6 (90/227)
TNP 630 (15.8) 42.2 (226/535)
Core basal 330 (8.3) 49.2 (151/307)
5NP 162 (4.1) 35.2 (50/142)
TNP not assignable 138 (3.4) 29.1 (25/86)
Unassignable 297 (7.4) 31.6 (31/98)
Total 3,992 (100) 32.4 (1,104/3,403)
5NP, five negative phenotype; AJCC, American Joint Committee on Cancer; ER,
estrogen receptor; HER2, human epidermal growth factor receptor-2; iTIL,
intratumoral tumor-infiltrating lymphocyte; TNP, triple-negative phenotype.
Liu et al. Breast Cancer Research 2012, 14:R48
http://breast-cancer-research.com/content/14/2/R48
Page 3 of 14
Tissue microarray and immunohistochemistry
The centralized provincial laboratory of Vancouver Gen-
eral Hospital retained single archival blocks for each of
the 3,992 patients. One 0.6-mm core per patient was
used, 17 TMAs representing these samples were con-
structed, and immunohistochemistry and scoring for ER,
PR, HER2, the Ki67 proliferation marker, EGFR, and
CK5/6 were performed as previously described
[31,37,39-42]. Immunohistochemistry for CD8+ TILs
was performed by using the antibody against human
CD8 (clone C8/144B, dilution 1:100) in accordance with
the protocol of the manufacturer (DakoCytomation,
Glostrup, Denmark). Intrinsic breast cancer subtypes
were determined by the immunohistochemical expres-
sions of ER, PR, HER2, Ki67, EGFR, and CK5/6. Lumi-
nal A was defined as ER+ or PR+, HER2-, and low Ki67
(< 14%); luminal B was defined as ER+ (or PR+) and
HER2- with high Ki67 (≥ 14%); luminal/HER2 subgroup
was defined as ER+ (or PR+) and HER2+; HER2+/ER-
was defined as HER2+ with ER- and PR- [42]; and triple-
negative subgroup (TNP) was defined as ER-, PR-, and
HER2-. The core basal subgroup was defined as triple-
negative with either EGFR+ or CK5/6+, and the five
negative phenotype (5NP) was defined as triple-negative
as well as EGFR- and CK5/6- [31]. The 3,992 patients
with breast cancer were thereby categorized as follows:
38.0% (1,518/3,992) luminal A, 20.8% (829/3,992) lumi-
nal B, 5.6% (223/3,992) luminal/HER2, 6.3% (250/3,992)
HER2+/ER-, and 15.8% (630/3,992) triple-negative, of
which 8.3% (330/3,992) could be categorized as core
basal and 4.1% (162/3,992) as 5NP; the remainder had a
partial or unassignable subtype because of missing or
ambiguous biomarker data (Table 1).
CD8+ tumor-infiltrating lymphocytes: scoring and
quantification
Stained TMA slides were digitally scanned and CD8+
TILs were visually scored by a pathologist who was
blinded to the clinical characteristics and outcomes of
the patients. Scoring and quantification of CD8+ TILs
were carried out as described in a recent study [24]. In
brief, intratumoral CD8+ TILs (iTILs) were defined as
CD8+ lymphocytes located within tumor cell nests or in
direct contact with the breast carcinoma malignant
epithelial cells, whereas stromal CD8+ TILs (sTILs) were
defined as CD8+ lymphocytes in the adjacent peritu-
moral stroma without direct contact with the carcinoma
cells. Total CD8+ TILs (tTILs) were measured by com-
bining the counts of iTILs and sTILs for each tissue
core. To assess the reproducibility and reliability of the
scoring, 490 cases were repeatedly scored by the same
pathologist after a period of time (4 weeks), and 200
cases were randomly selected from the whole cohort
and iTILs were re-scored by a second pathologist.
Pearson correlation analysis was used to check the relia-
bility of the repeated scoring by the same scorer, and
the intraclass correlation coefficient (ICC) was used to
assess the reliability of re-scoring by the two scorers.
High correlation coefficients were obtained (Pearson r
was at least 0.94, and ICC was 0.74).
Statistical analysis
The outcome variable in this study was breast cancer-
specific survival (BCSS). Optimal cutoff points for TILs
counts against BCSS were chosen on the basis of
recently published findings from an independent series
[24] and checked by receiver operating characteristic
curve analysis by using 10-year BCSS as the endpoints,
as described in the Supplemental method section (Addi-
tional file 1). The optimal cutoff points for iTIL, sTIL,
and tTIL used in this study were 1, 3, and 2, respec-
tively. To specify, CD8+ iTIL expression was categorized
as low when iTIL was 0 (no CD8+ iTIL counted) and
high when iTIL was at least 1 (1 or more CD8+ iTILs in
the assessed tissue core); sTIL low means fewer than 3
CD8+ sTILs per core, and tTIL low means fewer than 2
CD8+ tTILs were identified in a core.
Analysis of the association between TILs and clinico-
pathologic variables was performed by using SPSS ver-
sion 19.0 and R 2.11.1. Because the distributions of the
outcome variable (BCSS) were not normal in the study
cohort, non-parametric Wilcoxon testing was used to
check the bivariate relationship between BCSS and TILs
and other potential confounding variables, including age
at diagnosis, grade, tumor size, involvement of lymph
nodes, LVI, and intrinsic subtypes. Chi-squared testing
was used to check the relationship between TILs and
those potential confounding variables. For survival ana-
lysis, the event under study was death from breast can-
cer. BCSS time was defined as the number of years
between the date of diagnosis of breast cancer and the
date of death attributable to breast cancer. Survival time
was censored at the time a patient died from another
cause or when the follow-up period ended. For univari-
ate survival analyses, the Kaplan-Meier function analysis
was performed to estimate probabilities of BCSS. Log-
rank testing was used to assess differences in BCSS
among different subgroups. For multivariate survival
analyses, Cox proportional hazards regression models
were built to estimate the TIL hazard ratio (HR), which
was adjusted by the potential confounding variables on
the basis of the partial maximum likelihood estimation.
Smoothed, rescaled Schoenfeld residual plots were per-
formed to test proportional hazards assumptions. Only
cases with sufficient information for all covariates were
included in the multivariate analysis. Wald statistics
were used to test the significance of individual coeffi-
cients. Interactions between TILs and some covariables
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were checked by building Cox regression models for dif-
ferent levels of those variables and comparing HRs of
TILs. All of the tests were two-sided at a significance
level of 0.05. Supplementary analyses were also per-
formed by using relapse-free survival as an outcome
variable; relapse-free survival time was defined as the
number of years between the date of diagnosis of breast
cancer and the date of any type of relapse, including
local, regional, and distant relapses of the disease.
Results
CD8+ tumor-infiltrating lymphocyte counts and
distributions in breast cancer
Among the 3,992 breast tumor cases, intact cores bear-
ing infiltrating breast carcinoma sufficient for interpreta-
tion of immunohistochemical data for CD8 staining
were available from 3,403 (85.2%) tumors. Median
counts of CD8+ TILs per 0.6-mm TMA core were 0 for
iTIL (interquartile range, or IQR, of 0 to 1), 2 for sTIL
(IQR of 0 to 10), and 3 for tTIL (IQR of 0 to 12). Of
the 3,403 interpretable cases, 32.4% had tumor infil-
trated with at least one CD8+ iTIL and 60.6% by at least
one CD8+ sTIL (Figure S1 of Additional file 2). The dis-
tributions of CD8+ iTILs and sTILs were both signifi-
cantly and positively skewed (Figure S2 of Additional
file 3). Because analytical results from all types of TILs
interpretation were broadly similar, results presented in
this paper are based primarily on iTILs analysis, which
is the fastest and simplest to perform. As shown in
Table 1 the presence of iTIL is significantly associated
with young age, high grade, medullary histology, ER
negativity, HER2 positivity, and the core basal intrinsic
subgroup, the category that has the highest prevalence
of cases displaying intratumoral lymphocytes.
Prognosis of CD8+ iTILs in patients with breast cancer
(whole cohort)
To examine the prognosis of CD8+ TILs in the study
population, we first applied univariate Kaplan-Meier
function survival analysis in the whole cohort. The
results did not show a significant difference in BCSS
between breast cancer patients with an iTIL count of at
least 1 and an iTIL of 0 (P = 0.761). Since the distribu-
tion of iTILs was associated with patient age at diagno-
sis, tumor grade, and ER and HER2 status, we next
assessed the survival functions of iTIL associated with
BCSS in groups with different age, tumor grade, and ER
and HER2 status. Figure 1 showed that, in younger
patients (< 50 years) and in those with ER- tumors,
cases with iTILs had significantly better BCSS than
those without. Reversed associations were observed in
patients who were at least 50 years old or who had ER+
breast cancer. No significant associations were detected
in cases stratified by grade (grade 1 + 2 versus grade 3)
or HER2 status (HER2+ versus HER2-). These results
indicated that age and ER status could have an interac-
tion with the association between iTILs and patient sur-
vival in breast cancer.
We built Cox proportional hazards regression models
to estimate the HR for iTILs. Smoothed, rescaled
Schoenfeld residual plots showed that iTILs and most
other covariables satisfied the proportional hazards
assumptions well during the period of follow-up. Only
iTILs in the luminal A subgroup varied slightly during
longer follow-up.
Results from the univariate Cox regression model ana-
lysis showed that iTILs was not a significant prognostic
factor associated with BCSS in the cohort as a whole:
HR = 1.02, 95% confidence interval (CI) = 0.89 to 1.17.
To take into consideration potential confounders, a mul-
tivariate Cox regression model was built to assess the
association between iTILs and BCSS, including the cov-
ariates of age at diagnosis, tumor grade and size, lymph
node status, LVI, and intrinsic subtype. Table 2 showed
that the adjusted HR of iTIL was 0.79 (95% CI = 0.68 to
0.91), meaning that, in the whole cohort, the probability
of BCSS among patients with an iTIL count of at least 1
was 21% (1 to 0.79) higher than among those with an
iTIL count of 0 after adjustment for age, grade, tumor
size, lymph node status, LVI, and intrinsic subtypes.
Besides iTIL, tumor grade and size, nodal status, LVI,
and intrinsic subtype, each had significant effects on
BCSS. To examine the effect of interaction between age,
ER status, and iTIL, we built multivariate Cox regression
models for iTILs at different levels of age and ER status.
These analyses showed that the adjusted HRs for iTILs
were 0.65 (95% CI = 0.51 to 0.84) for those younger
than 50 years old and 0.89 (95% CI = 0.74 to 1.06) for
those at least 50 years old; the adjusted HRs were 0.61
(95% CI = 0.47 to 0.77) for those with ER- tumors but
0.91 (95% CI = 0.77 to 1.11) for those with ER+ tumors.
Therefore, interactions between iTIL and age and ER
status might modify the effect size for iTILs in the
unstratified whole cohort of patients with breast cancer.
Association of CD8+ iTILs with breast cancer-specific
survival in different breast cancer intrinsic subgroups
We further assessed the association of CD8+ TILs with
patient survival in different breast cancer intrinsic sub-
types, first using univariate Kaplan-Meier function survi-
val analysis. No difference in BCSS was detected
between those with an iTIL count of at least 1 and an
iTIL count of 0 within the luminal A and luminal B
subgroups (Figure 2a, b). Although we observed an
apparent difference between the two groups among
HER2+/ER- cases, this was not statistically significant (P
= 0.064) (Figure 2c). However, as shown in Figure 2d, a
large and significant difference in BCSS was found
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between cases with an iTIL count of at least 1 and those
with an iTIL count of 0 among triple-negative breast
cancers. By stratifying triple-negatives into core basal
and 5NP subgroups, we observed a much larger differ-
ence in BCSS between cases with an iTIL count of at
least 1 and those with an iTIL count of 0 in the core
basal intrinsic subgroup. Patients with an iTIL count of
at least 1 basal-like tumor had significantly better survi-
val than those with an iTIL count of 0 (mean survival
time of 14.5 vears versus 11.0 years, P < 0.001) (Figure
2e). No such association was found among triple-nega-
tive, non-basal (5NP) cases (Figure 2f). We also per-
formed survival analysis in all patients with ER- breast
cancer, excluding the core basal cases, and found no sig-
nificant difference in BCSS between cases with an iTIL
count of at least 1 and those with an iTIL count of 0 (P
= 0.434).
To confirm the association between iTIL and BCSS
and to assess the independent prognostic effect size in
different breast cancer intrinsic subgroups, multivariate
Cox proportional hazards regression models were built
to estimate the iTIL HRs, which were adjusted by the
potential confounders. Results in Table 3 showed that
the HRs of iTIL were not significant in the luminal A,
luminal B, and HER2+/ER- intrinsic subgroups. How-
ever, iTIL was demonstrated to be a significantly
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Figure 1 Breast cancer-specific survival (BCSS) by intratumoral tumor-infiltrating lymphocytes (iTILs) among groups with different age
and estrogen receptor (ER) status. (a) Age of less than 50 years, (b) age of at least 50 years, (c) ER-, and (d) ER+. CI, confidence interval.
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independent favorable factor for BCSS in triple-negative
cases because of a strong effect in the core basal sub-
group (Table 4). Among core basal cases, the presence
of any intratumoral CD8+ lymphocytes (iTILs of at least
1) was associated with a 65% higher probability of BCSS
than among those tumors lacking intratumoral CD8+
lymphocytes (iTIL of 0) and this was statistically signifi-
cant even after adjusting for age at diagnosis, grade,
tumor size, lymph node status, and LVI. Considering
that medullary breast carcinoma, a histologically evident
subtype known to carry a good prognosis, usually has a
core basal immunophenotype and could be responsible
for some of the observed effect, we repeated the multi-
variate Cox regression analysis for core basal cases by
excluding those with medullary carcinoma (27 cases).
The results still showed a similar and significant HR
(HR = 0.38, 95% CI = 0.24 to 0.59), which therefore
could not be attributed to medullary histology. In con-
trast, the multivariate analysis did not show any associa-
tion between iTILs and BCSS in the 5NP subgroup (that
is, triple-negative breast cancers that do not express
basal markers). These results demonstrated that the
prognostic effect of iTILs was significantly different in
these two subgroups of triple-negative cases, indicating
that the association of iTIL with BCSS exists primarily
in only the core basal intrinsic subgroup.
Association of CD8+ sTILs and tTILs with clinical outcome
To confirm the prognostic value of CD8+ TILs in breast
cancer, we also evaluated the distributions of sTILs and
tTILs in relation to patient and tumor characteristics
and the associations of sTILs and tTILs with survival.
Results similar to those from the analysis with iTILs
were obtained. In brief, high expressions of sTILs and
tTILs were significantly correlated with young age, high
grade, larger tumor size, medullary histology, ER nega-
tivity, HER2 positivity, and the core basal phenotype
(Table S1 of Additional file 4) and again were signifi-
cantly associated with better BCSS in only the core
basal intrinsic subgroup (Figure S3 of Additional file 5
and Tables S2 and S3 of Additional file 4).
Discussion
The prognostic significance of TILs in breast cancer has
been debated, but no consistent conclusion has yet been
drawn. We implemented this study, using a particularly
large, well-annotated cohort comprising nearly 4,000
patients, in an attempt to definitively assess the clinical
implication of TILs in breast cancer. In addition to
addressing the question of whether immune response
(as measured by CD8+ TILs) has a prognostic role in
breast cancer in general, we examined the effect of TILs
in the major breast cancer intrinsic biological subtypes.
To our knowledge, this is the first study sufficiently
powered for multivariate analysis to investigate the asso-
ciation of CD8+ TILs with patient survival within the
breast cancer intrinsic subtypes. Our results demon-
strate that the presence of iTILs is independently asso-
ciated with a significantly superior outcome in women
with diagnosed core basal tumors. Although the
Table 2 Hazards for breast cancer-specific survival in the whole cohort with univariate and multivariate analyses
Variable Univariate analysis Multivariate analysis
n = 3,144
HR (95% CI) P value HR (95% CI) P value
Age
≥ 50 vs. < 50 years 0.85 (0.75-0.96) 0.011 1.01 (0.88-1.16) 0.884
Grade
3 vs. 1 and 2 2.12 (1.87-2.41) < 0.001 1.57 (1.35-1.82) < 0.001
Tumor size
> 2 vs. ≤ 2 cm 2.17 (1.92-2.45) < 0.001 1.59 (1.36-1.83) < 0.001
Nodal status
Positive vs. negative 2.79 (2.48-3.15) < 0.001 2.05 (1.76-2.39) < 0.001
Lymphovascular invasion
Positive vs. negative 2.25 (1.99-2.54) < 0.001 1.29 (1.10-1.51) 0.001
Subtype
Luminal B vs. luminal A 2.08 (1.78-2.45) < 0.001 1.75 (1.46-2.09) < 0.001
HER2+/ER- vs. luminal A 2.98 (2.40-3.70) < 0.001 2.51 (2.99-3.19) < 0.001
Core basal vs. luminal A 2.30 (1.87-2.84) < 0.001 2.02 (1.58-2.58) < 0.001
5NP vs. luminal A 1.65 (1.30-2.10) 0.002 1.49 (1.12-1.97) 0.011
iTIL
≥ 1 vs. 0 1.02 (0.89-1.17) 0.761 0.79 (0.68-0.91) < 0.001
5NP, five negative phenotype; CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; HR, hazard ratio; iTIL, intratumoral
tumor-infiltrating lymphocyte.
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iTIL ≥ 1  n = 226  event = 57 
iTIL = 0  n = 309  event = 121
iTIL ≥ 1  n = 90  event = 35 
iTIL = 0  n = 137  event = 70
iTIL = 0  n = 50  event = 14
iTIL ≥ 1  n = 92  event = 24
iTIL ≥ 1  n = 151  event = 38
 
iTIL = 0  n = 156  event = 74
iTIL = 0  n = 1039 event = 197 
iTIL ≥ 1  n = 353  event = 79
Years of follow-up                                                          Years of follow-up
iTIL ≥ 1  n = 285  event = 102
 
iTIL = 0  n = 488  event = 175
Years of follow-up                                                          Years of follow-up
Years of follow-up                                                          Years of follow-up
iTIL = 0  15-year BCSS 77% (95% CI, 73-81)                                      iTIL = 0  15-year BCSS 57% (95% CI, 51-63)
iTIL ≥ 1  15-year BCSS 77% (95% CI, 73-81)                                      iTIL ≥ 1  15-year BCSS 60% (95% CI, 54-66)
Luminal A; p = 0.104                                                                            Luminal B; p = 0.506  
iTIL = 0  15-year BCSS 48% (95% CI, 40-56)                                      iTIL = 0  15-year BCSS 60% (95% CI, 54-66)
iTIL ≥ 1  15-year BCSS 61% (95% CI, 51-71)                                      iTIL ≥ 1  15-year BCSS 74% (95% CI, 68-80)
HER2+/ER-; p = 0.064                                                                           TNP; p = 0.001  
iTIL = 0  15-year BCSS 52% (95% CI, 44-60)                                      iTIL = 0  15-year BCSS 72% (95% CI, 62-82)
iTIL ≥ 1  15-year BCSS 74% (95% CI, 66-82)                                      iTIL ≥ 1  15-year BCSS 71% (95% CI, 59-83)





























































Figure 2 Breast cancer-specific survival (BCSS) by intratumoral tumor-infiltrating lymphocytes (iTILs) in different breast cancer intrinsic
subgroups. (a) Luminal A, (b) luminal B, (c) HER2+/ER-, (d) triple-negative phenotype, (e) core basal phenotype, and (f) five negative phenotype
subgroups. CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2.
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presence of CD8+ iTILs is also an independent prognos-
tic indicator for improved patient survival in triple-nega-
tive breast cancers, this favorable prognostic effect
cannot be detected among those lacking expression of
basal biomarkers (5NP). In the core basal subgroup,
patients having tumors with CD8+ iTILs survived an
average of 3.5 years longer than did patients with basal
tumors lacking evidence of a CD8+ iTIL immune
response.
Breast cancer is both clinically and molecularly het-
erogeneous and is, in practice, stratified by hormonal
receptors (ER and PR), by HER2 status, and, increas-
ingly, by expression of other biomarkers such as Ki67 or
by gene expression profiling methodologies. Dissecting
the heterogeneity of breast cancer is critically important
for understanding the underlying mechanisms of the
disease and for identifying subpopulations that are most
likely to respond to particular therapies [43]. In general,
ER- breast cancers have a worse prognosis than those
that are ER+, but not all patients with ER- breast cancer
have poor survival. Teschendorf and colleagues [44]
applied an integrative analysis of three gene expression
datasets to assess the prognostic value of molecular sig-
natures and found that most prognostic markers of bet-
ter prognosis in ER- breast cancer are associated with
the activation of immune response pathways. Further-
more, a seven-gene immune response classifier was con-
structed and showed significant good prognostic value
in patients with ER- breast cancer [45]. Meta-analytic
studies of clinical and gene expression data have
demonstrated that immune response is significantly
associated with prognosis in breast cancer [46], primar-
ily in rapidly proliferating [47] and ER- [48,49] sub-
groups. Results from some studies indicate that TILs
could be a protective factor reducing the likelihood of
distant metastasis in patients with triple-negative breast
Table 3 Hazards for breast cancer-specific survival with multivariate analysis in the luminal A, luminal B, and HER2
+/ER- intrinsic subgroups
Variable Luminal A (n = 1,276) Luminal B (n = 709) HER2+/ER- (n = 216)
HR P HR P HR P
Age 1.38 1.04 1.13
≥ 50 vs. < 50 years (1.02-1.86) 0.037 (0.81-1.35) 0.750 (0.75-1.70) 0.564
Grade 1.75 1.28 2.13
3 vs. 1 and 2 (1.36-2.25) < 0.001 (0.99-1.67) 0.062 (1.21-3.76) 0.009
Tumor size 1.64 1.49 1.73
> 2 vs. ≤ 2 cm (1.28-2.11) < 0.001 (1.14-1.95) 0.004 (1.11-2.68) 0.015
Nodal status 2.20 1.75 1.75
Positive vs. negative (1.65-2.95) < 0.001 (1.31-2.32) < 0.001 (1.07-2.83) 0.025
Lymphovascular invasion 1.12 1.33 1.36
Positive vs. negative (0.84-1.49) 0.444 (0.99-1.77) 0.056 (0.84-2.18) 0.211
iTIL 1.14 0.85 0.76
≥ 1 vs. 0 (0.86-1.50) 0.357 (0.66-1.11) 0.235 (0.50-1.15) 0.194
ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; HR, hazard ratio; iTIL, intratumoral tumor-infiltrating lymphocyte.
Table 4 Hazards for breast cancer-specific survival with multivariate analysis in TNP, core basal, and 5NP groups
Variable TNP (n = 496) Core basal (n = 287) 5NP (n = 130)
HR P HR P HR P
Age 0.90 0.91 1.07
≥ 50 vs. < 50 years (0.66-1.22) 0.488 (0.62-1.35) 0.648 (0.54-2.14) 0.830
Grade 1.74 1.54 1.81
3 vs. 1 and 2 (1.11-2.70) 0.015 (0.80-2.97) 0.201 (0.74-4.41) 0.191
Tumor size 1.66 1.85 1.49
> 2 vs. ≤ 2 cm (1.19-2.30) 0.003 (1.23-2.79) 0.003 (0.71-3.12) 0.293
Nodal status 2.00 2.16 1.58
Positive vs. negative (1.42-2.83) < 0.001 (1.39-3.35) 0.001 (0.73-3.42) 0.244
Lymphovascular invasion 1.55 1.52 3.13
Positive vs. negative (1.08-2.21) 0.017 (0.97-2.36) 0.065 (1.27-7.77) 0.013
iTIL 0.48 0.35 0.99
≥ 1 vs. 0 (0.34-0.67) < 0.001 (0.23-0.54) < 0.001 (0.48-2.04) 0.986
5NP, five negative phenotype; HR, hazard ratio; iTIL, intratumoral tumor-infiltrating lymphocyte; TNP, triple-negative phenotype.
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tumors [50] and among those with medullary carcinoma
[17]. Moreover, two recently published gene expression
profiling studies demonstrated that effective immune
(particularly cytotoxic T-cell) response plays a favorable
prognostic role in basal breast cancer subgroups [51,52].
In our study, the multivariate analysis clearly demon-
strates that the presence of CD8+ iTILs has a different
prognostic value in breast cancer with different intrinsic
biological subtypes. Even among the triple-negative
cases, immune response has different meanings in core
basal versus ‘five negative’ phenotypes. Evidence from
previous studies has shown that core basal-like tumors
are associated with a poorer prognosis and appear biolo-
gically different from 5NP tumors [31,32]. Our results
suggest that local immune response characterized by
CD8+ lymphocyte infiltration might be considered an
important factor differentiating the core basal from 5NP
breast tumors within the class of triple-negative breast
cancers.
Tumor-infiltrating lymphocytes and macrophages are
thought to be molecular determinants of clinical out-
come in breast cancer. Although cytotoxic T lympho-
cytes and natural killer cells have been found to have
antitumor activity, some lymphocytes such as B cells
exhibit bipolar roles in breast cancer development. Dis-
tinct cell-mediated immune responses also play antago-
nistic roles in disease prognosis. T helper cell 1 (Th1)-
mediated immune response pathways are considered to
have an inhibitory effect, whereas Th2 immune response
pathways may promote development and metastasis of
breast cancer. It has been found that CD4+ T lympho-
cytes can promote metastasis by activating the EGFR
signaling pathway in a Th2-type tumor microenviron-
ment [53]. Identification of interactions between
immune response and other molecular pathways may
define novel prognostic subtypes. In ER- breast cancer,
those characterized with high expression of EGFR and
low expression of Th1-mediated pathway-related mar-
kers such as interleukin-12 and interferon-gamma were
found to have a poor prognosis [54]. TILs in the tumor
microenvironment are predominantly CD8+ T cells
[55,56], which are considered to be the effector cells in
Th1 antitumor immune responses. CD8+ T cells pro-
duce interferon-gamma through interaction with tumor-
related antigens, potential leading to tumoricidal activity
by induction of apoptosis or macrophage tumor killing
activity or both [57]. Studies indicate that tumor-specific
or even non-cancer-specific antigens such as p53 and b-
actin are common targets of cytotoxic T lymphocytes
and can induce immunological and clinical effects in
patients with breast cancer [58-60]. Findings from our
study suggest that core basal-like breast cancer is more
immunogenic than other intrinsic subgroups, as mea-
sured by CD8+ T-cell infiltration. Tumors of this
subtype have a high expression of basal markers, some
of which (such as EGFR) may interact with T cell-
mediated immune response to affect clinical outcome in
breast cancer. We would suggest a hypothesis that cer-
tain ‘basal proteins’ expressed on the cell surface can be
recognized as tumor antigens and that the consequent
induction of adaptive basal marker-specific immunity
can enhance the local Th1-mediated antitumor immune
response in these breast cancers. The absence of these
surface markers in 5NP breast cancers could underpin
the observed difference in prognostic significance of
TILs in core basal compared with 5NP breast cancers.
Recent studies have suggested that a pre-existing
immune response can strengthen the effect of conven-
tional chemotherapy [61,62], enhancing destruction of
tumor cells [63], and this favorable effect could become
stronger in patients with highly immunogenic tumors,
perhaps including the core basal group. Basal-like breast
cancers have distinctive survival patterns, many relapses
and deaths during the first 5 years after diagnosis, but
fewer events after this period [32], indicating that basal-
like breast cancers encompass both poor and good prog-
nostic subgroups responding variably to conventional
therapies. In our cohort, systemic treatment decisions
were not randomized, making outcomes stratified by
treatment difficult to interpret; nevertheless, an explora-
tory analysis suggests that pre-treatment CD8+ lympho-
cyte infiltration is an independent favorable predictive
indicator of good outcomes in basal-like cases treated
with chemotherapy (HR = 0.29, 95% CI = 0.16 to 0.55, P
< 0.001, n = 107) (Table S4 of Additional file 4). Our
results indicate that efforts toward developing immuno-
stimulative therapies might be best directed to the core
basal group. The recognition of tumor-associated anti-
gens by CD8+ cells is a significant contributor to the
detection and ultimate destruction of tumor cells [64].
Basal-like breast cancer could be particularly suitable for
targeted immunotherapy. The lack of success of prior
attempts at immunotherapy for breast cancer may be
attributable, in part, to the lack of focus on appropriate
breast cancer subtypes. A better understanding of the
interaction between immune response, intrinsic subtype,
AST, and patient outcome is critical to more effective
and targeted clinical management for patients with breast
cancer, especially those with basal-like breast tumors.
Studies on TILs in breast cancer have come to incon-
sistent conclusions. We believe that one of the underly-
ing reasons could be inconsistency in defining and
measuring TILs. Some research considered only the pre-
sence of peritumoral stromal lymphocytes [65,66], and
many considered all T lymphocytes (which might
include larger numbers of regulatory T cells that could
in some cases reflect immune suppression instead of
activation). In our study, specific immunohistochemistry
Liu et al. Breast Cancer Research 2012, 14:R48
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was used with a mouse monoclonal anti-human CD8
antibody to detect cytotoxic effector CD8+ TILs in intra-
tumoral and stromal locations for each tumor tissue
core. We evaluated the reliability of repeated scoring by
the same scorer and between different scorers, and it
was demonstrated that our visual CD8+ TILs scoring
was highly reliable (Figure S4 of Additional file 6). Ana-
lyses with intratumoral, stromal, and total CD8+ TILs
were conducted, and consistent results were obtained.
We also did analyses using relapse-free survival as an
outcome and obtained results similar to those using
BCSS as the outcome (Figures S5 and S6 of Additional
files 7 and 8 and Tables S5 to S7 of Additional file 4).
Thus, we are confident that the identification and quan-
tification of TILs and the assessment of the association
of TILs with clinical outcome in breast cancer are reli-
able and valid in this study. One potential limitation of
our methods is that TMAs may not adequately repre-
sent breast tumor heterogeneity. Several studies never-
theless have shown that findings from TMAs are
consistent with those from full-face tissue sections
[67,68]. Although we observed a trend to a favorable
prognostic effect of CD8 TILs in the HER2+/ER- sub-
group (and this trend is consistent with a gene expres-
sion study [69]), the effect was not statistically
significant in our univariate or multivariate analyses.
Research with more power particularly for this subgroup
needs to be done to draw a more definitive conclusion
among HER2+ cases. We were not able to measure
changes in immune response induced by chemotherapy,
as all of the tissue samples were collected before
patients received systemic therapy. Further studies
would need to be conducted to assess the interaction of
TILs with chemotherapy, ideally in randomized trials.
Conclusions
This study provides strong evidence that CD8+ lympho-
cyte infiltration is an independent factor associated with
improved survival in patients with breast cancer. The
favorable prognostic effects of TILs occur mostly in the
basal-like intrinsic subgroup.
Additional material
Additional file 1: Validation of the cutoff points of TILs. The
Supplemental method section explained how the receiver operating
characteristic (ROC) analysis was used to validate the optimal cutoffs of
TILs chosen from an independent study. To take into consideration that
outcome variable, breast cancer specific survival, is a time to event
endpoint, X-tile software was also used to validate the optimal cut-offs,
and the same cutoff points of iTIL and sTIL were obtained as those from
the ROC method.
Additional file 2: CD8+ TILs in breast cancer. This image showed
some examples of CD8+ iTIL and sTIL in a breast tumor sample (scale
bar: 50 μm). Information with respect to availability of all of our CD8
staining images were provided in the figure legend.
Additional file 3: Distributions of CD8+ iTIL and sTIL in the whole
cohort. Histograms were used to show the distributions of CD8+ iTIL
and sTIL in the whole study population. Values on the X-axis represent
absolute counts of CD8+ iTIL (A) or sTIL (B) per tissue microarry core.
Additional file 4: Supplemental tables. Table S1 showed the
distributions of CD8+ sTIL and tTIL in relation to patient and tumor
characteristics. Table S2 showed the hazard ratios (HRs) of sTIL and tTIL
in the whole cohort with multivariate Cox regression analysis, adjusted
by age at diagnosis, tumor grade and size, lymph node status,
lymphovascular invasion, and intrinsic subtype. Table S3 showed the HRs
of sTIL and tTIL in triple negative (TNP), core basal (CBP), and five
negative (5NP) breast cancer intrinsic subgroups in multivariate analysis.
Table S4 showed the HRs of iTIL, sTIL and tTIL in patients without
adjuvant systemic therapy (AST) and with chemotherapy in multivariate
analysis. Table S5 showed HRs of iTIL in the whole cohort with univariate
and mulvariate analysis, using relapse-free survival (RFS) as the outcome
variable. Tables S6 and S7 showed the HRs of iTIL in different intrinsic
subgroups with multivariate Cox regression analysis using RFS as the
outcome variable.
Additional file 5: Breast cancer specific survival (BCSS) by sTIL and
tTIL in different breast cancer intrinsic subgroups. Kaplan-Meier
function survival analysis of association of TILs with BCSS: (A) sTIL in triple
negative (TNP), (B) tTIL in TNP, (C) sTIL in core basal (CBP), (D) tTIL in CBP,
(E) sTIL in five negative (5NP), and (F) tTIL in 5NP.
Additional file 6: Correlation of re-scoring of CD8+ TILs by the
same and different pathologists. The scatter plots demonstrated
correlations of repeated scoring for 490 cases by the same pathologist
for CD8+ iTIL (A) and sTIL (B), and re-scoring of CD8+ iTIL for 200 cases
by two pathologists (C).
Additional file 7: Relapse-free survival (RFS) by iTIL among groups
with different age and ER status. Kaplan-Meier function survival
analysis of association between iTIL and RFS in: (A) age < 50 year, (B) age
≥ 50 year; (C) ER-, and (D) ER+.
Additional file 8: Relapse-free survival (RFS) by iTIL in different
breast cancer intrinsic subgroups. Kaplan-Meier function survival
analysis of association between iTIL and RFS in: (A) luminal A, (B) luminal
B, (C) HER2+/ER-, (D) Triple negative, (E) core basal, and (F) five negative
subgroups.
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